Journal
CANCER LETTERS
Volume 351, Issue 1, Pages 30-40Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2014.05.019
Keywords
HER2; Gastric cancer; Trastuzumab; Review
Categories
Funding
- Roche Farma, Spain
Ask authors/readers for more resources
Identification of the importance of human epidermal growth factor receptor-2 (HER2) status, biomarker testing and the development of anti-HER2 treatments have changed the prognosis of breast and gastric cancers. The addition of trastuzumab to chemotherapy has improved outcomes for patients with HER2-positive metastatic adenocarcinoma of the stomach and gastroesophageal junction, but some relevant issues remain to be elucidated or will emerge with new drugs. This article reviews the current state of HER2 in gastric cancer focusing on diagnostic and anti-HER2 targeted treatment issues and the role of trastuzumab in localized disease, and its combination or integration with new therapies. (C) 2014 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available